Most digital health business cases lean on health economics methods designed for pharmaceuticals, and quietly ignore the parts of value those methods can’t see. Here’s what the established toolkit
can do, where it strains, and why a credible DHT business case in 2026 needs more than a QALY
model.
NICE Evidence Standard 2 reads as a UX requirement. It functions as a health equity standard — the line where DHT founders quietly decide which patients their product will work for.
NICE Evidence Standard 18 is the cost-effectiveness analysis most DHT founders treat as compliance — and the threshold that frames it has just moved for the first time in 27 years.
NICE ESF Standard 6 demands a clinical governance design, not a clinician disclaimer. Here’s what proportionate oversight actually looks like for founders.
32% of consumers now use AI chatbots for health information. For DHT founders, your real competitor isn’t the care pathway — it’s a free chatbot.
Why most DHT companies fail NICE Evidence Standard 15 — and how to design a real-world evidence programme that survives contact with the NHS.
NICE Evidence Standard 12 forces every DHT to answer one question: do you replace something, or add to it? The answer decides whether you ever scale.
NICE Evidence Standard 1 is the safety and quality foundation for any NHS-bound DHT. Why founders mis-read it, and what good looks like.
NICE Evidence Standard 4 requires DHTs to demonstrate bias mitigation across protected groups — not just document it. Here’s what it actually demands, where founders get it wrong, and how to build products that hold up under NHS scrutiny
Concept Development and Planning: Laying the Groundwork for Your Digital Health Tool Ever wondered how to turn your brilliant digital
